uric acid has been researched along with Abnormality, Heart in 23 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pharmacologic protection trial was conducted to test the hypothesis that allopurinol, a scavenger and inhibitor of oxygen free radical production, could reduce death, seizures, coma, and cardiac events in infants who underwent heart surgery using deep hypothermic circulatory arrest (DHCA)." | 5.09 | Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. ( Clancy, RR; Gaynor, JW; Goin, JE; Hirtz, DG; Jacobs, ML; Mahle, WT; McGaurn, SA; Murphy, JD; Nicolson, SC; Norwood, WI; Spray, TL; Steven, JM; Wernovsky, G, 2001) |
| "Hyperuricemia has been associated with cardiovascular risk factors but it remains controversial if uric acid is an independent predictor of cardiac mortality." | 3.88 | Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death. ( Martínez-Quintana, E; Riaño-Ruiz, M; Rodríguez-González, F; Rodríguez-Hernández, JL, 2018) |
| " These results were obtained with an average dosage of 19 +/- 4." | 1.29 | [Long-term hematological management of cyanotic congenital heart diseases]. ( Cornu, P, 1994) |
| "Uric acid excretion was measured in hyperuricaemia group." | 1.29 | Hyperuricaemia in cyanotic congenital heart disease. ( Akita, H; Hayabuchi, Y; Kuroda, Y; Matsuoka, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 2 (8.70) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, B | 1 |
| Zeng, Y | 1 |
| Zhao, Z | 1 |
| Han, F | 1 |
| Liu, T | 1 |
| Wang, J | 1 |
| Khalique, A | 1 |
| Lu, WJ | 1 |
| Chong, J | 1 |
| Lan, F | 1 |
| He, H | 1 |
| Rodríguez-Hernández, JL | 1 |
| Rodríguez-González, F | 2 |
| Riaño-Ruiz, M | 1 |
| Martínez-Quintana, E | 2 |
| Rokicki, W | 1 |
| Strzałkowski, A | 1 |
| Kłapcińska, B | 1 |
| Danch, A | 1 |
| Sobczak, A | 1 |
| Mace, SE | 1 |
| Newman, AJ | 1 |
| Liebman, J | 1 |
| Yip, WC | 1 |
| Tay, JS | 1 |
| Ho, TF | 1 |
| Ellis, EN | 1 |
| Brouhard, BH | 1 |
| Conti, VR | 1 |
| Lorant, P | 1 |
| Kremeier, E | 1 |
| Young, D | 1 |
| Cornu, P | 1 |
| Perloff, JK | 2 |
| Hayabuchi, Y | 1 |
| Matsuoka, S | 1 |
| Akita, H | 1 |
| Kuroda, Y | 1 |
| Clancy, RR | 1 |
| McGaurn, SA | 1 |
| Goin, JE | 1 |
| Hirtz, DG | 1 |
| Norwood, WI | 1 |
| Gaynor, JW | 1 |
| Jacobs, ML | 1 |
| Wernovsky, G | 1 |
| Mahle, WT | 1 |
| Murphy, JD | 1 |
| Nicolson, SC | 1 |
| Steven, JM | 1 |
| Spray, TL | 1 |
| Laurens, P | 1 |
| Gavelle, P | 1 |
| Maurice, P | 1 |
| Dubost, C | 1 |
| Mertz, DP | 1 |
| Rusteborg, J | 1 |
| Teodosiev, L | 1 |
| Dearth, JC | 1 |
| Tompkins, RB | 1 |
| Giuliani, ER | 1 |
| Feldt, RH | 1 |
| Hsu, AC | 1 |
| Kooh, SW | 1 |
| Izukawa, T | 1 |
| Fox, IH | 1 |
| Ramírez, JA | 1 |
| Ferraris, JR | 1 |
| Galvez, H | 1 |
| Schnitzler, E | 1 |
| Vargas, JF | 1 |
| Ross, EA | 1 |
| Danovitch, GM | 1 |
| Child, JS | 1 |
| Canobbio, MM | 1 |
| Denninger, K | 1 |
| Leff, LO | 1 |
| Smith, JP | 1 |
| Chevallier, J | 1 |
| Michelet, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease: An Open Label Trial[NCT00459225] | 0 participants (Actual) | Interventional | 2007-04-30 | Withdrawn (stopped due to Difficulty recruiting subjects) | |||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation[NCT02519335] | Phase 1 | 12 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to PI no longer at this facility) | ||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery[NCT04997291] | Phase 1 | 12 participants (Anticipated) | Interventional | 2021-04-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uric acid and Abnormality, Heart
| Article | Year |
|---|---|
Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism.
Topics: Arthritis, Gouty; Cyanosis; Heart Defects, Congenital; Hematologic Diseases; Humans; Kidney; Uric Ac | 1993 |
1 trial available for uric acid and Abnormality, Heart
| Article | Year |
|---|---|
Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
Topics: Allopurinol; Cardiac Surgical Procedures; Coma; Death, Sudden, Cardiac; Female; Free Radical Scaveng | 2001 |
Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
Topics: Allopurinol; Cardiac Surgical Procedures; Coma; Death, Sudden, Cardiac; Female; Free Radical Scaveng | 2001 |
Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
Topics: Allopurinol; Cardiac Surgical Procedures; Coma; Death, Sudden, Cardiac; Female; Free Radical Scaveng | 2001 |
Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.
Topics: Allopurinol; Cardiac Surgical Procedures; Coma; Death, Sudden, Cardiac; Female; Free Radical Scaveng | 2001 |
21 other studies available for uric acid and Abnormality, Heart
| Article | Year |
|---|---|
Uric acid: a potent molecular contributor to pluripotent stem cell cardiac differentiation via mesoderm specification.
Topics: Ascorbic Acid; Cell Differentiation; Cell Lineage; Cell Proliferation; Epithelial-Mesenchymal Transi | 2019 |
Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death.
Topics: Adult; Biomarkers; Cause of Death; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hyp | 2018 |
Hyperuricaemia in congenital heart disease patients.
Topics: Adolescent; Adult; Biomarkers; C-Reactive Protein; Female; Follow-Up Studies; Heart Defects, Congeni | 2015 |
Antioxidant status in newborns and infants suffering from congenital heart defects.
Topics: Analysis of Variance; Antioxidants; Biomarkers; Case-Control Studies; Catalase; Female; Glutathione | 2003 |
Impairment of urate excretion in patients with cardiac disease.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Female; Heart Defects, Congenital; Hemodyna | 1984 |
Hyperuricaemia as a cause of acute renal failure complicating cardiopulmonary bypass surgery.
Topics: Acute Kidney Injury; Adolescent; Cardiopulmonary Bypass; Child; Child, Preschool; Heart Defects, Con | 1983 |
Renal function in children undergoing cardiac operations.
Topics: Acute Kidney Injury; Cardiac Surgical Procedures; Child; Child, Preschool; Cyanosis; Heart Defects, | 1983 |
[Cardiovascular diseases in Vienna. Epidemiological results of the "Vienna Health Study 1979"].
Topics: Adult; Austria; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol; Coronary Disease; F | 1981 |
Hyperuricemia in cyanotic congenital heart disease.
Topics: Adolescent; Adult; Allopurinol; Arthritis; Child; Child, Preschool; Gout; Heart Defects, Congenital; | 1980 |
[Long-term hematological management of cyanotic congenital heart diseases].
Topics: Adolescent; Adult; Child; Child, Preschool; Heart Defects, Congenital; Hematologic Diseases; Humans; | 1994 |
Hyperuricaemia in cyanotic congenital heart disease.
Topics: Acetylglucosaminidase; Adolescent; Adult; Age Factors; Child; Child, Preschool; Creatinine; Heart De | 1993 |
[Incidence of hyperuricemia in atrioventricular block. Systematic study of 158 cases which required implantation of an isotopic cardiac pacemaker].
Topics: Adolescent; Adult; Aged; Child; Female; Heart Block; Heart Defects, Congenital; Humans; Male; Middle | 1978 |
[Duplication of the left atrioventricular orifice (author's transl)].
Topics: Adult; Allopurinol; Arrhythmias, Cardiac; Blood Glucose; Cardiomegaly; Cholesterol; Diphosphates; El | 1975 |
[Excretion of uric acid in cardiac decompensation].
Topics: Adolescent; Adult; Cardiomyopathies; Chronic Disease; Female; Glomerular Filtration Rate; Heart Defe | 1979 |
Hyperuricemia in congenital heart disease.
Topics: Adolescent; Cyanosis; Female; Heart Defects, Congenital; Humans; Male; Polycythemia; Retrospective S | 1978 |
Uric-acid lithiasis in an infant with cyanotic congenital heart disease.
Topics: Allopurinol; Heart Defects, Congenital; Humans; Infant; Infant, Newborn; Kidney Calculi; Male; Purin | 1977 |
[Postoperative hyperuricemia of cyanotic and acyanotic congenital cardiopathies].
Topics: Cardiopulmonary Bypass; Child; Child, Preschool; Creatinine; Glomerular Filtration Rate; Heart Defec | 1991 |
Renal function and urate metabolism in late survivors with cyanotic congenital heart disease.
Topics: Adult; Creatine; Female; Glomerular Filtration Rate; Heart Defects, Congenital; Humans; Kidney; Kidn | 1986 |
[Polycythemia, polyglobulia and gout].
Topics: Cyanosis; Erythropoiesis; Female; Gout; Heart Defects, Congenital; Humans; Leukemia; Male; Nucleic A | 1973 |
Achalasia in children and adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystoscopy; Female; Heart Defects, Congenital; Hematuria | 1973 |
[Analytical and statistical study of blood uric acid in 90 cases of congenital cyanotic cardiopathies in children].
Topics: Child; Cyanosis; Female; Heart Defects, Congenital; Humans; Male; Uric Acid | 1966 |